L’acumulaci\u00f3 de ferro i l’envelliment cel\u00b7lular s’han relacionat amb la fibrosi hep\u00e0tica, una condici\u00f3 en qu\u00e8 el fetge desenvolupa teixit fibr\u00f3s (a mode de cicatriu) a causa d’un dany cr\u00f2nic, com passa a l’hepatitis cr\u00f2nica i el c\u00e0ncer de fetge. Tot i que s’ha identificat la connexi\u00f3 entre aquests dos factors, no s’havia investigat a fons com podrien estar mecan\u00edsticament relacionats. En aquest sentit, un nou estudi, liderat per la investigadora de l’IDIBELL Isabel Fabregat, aborda aquesta q\u00fcesti\u00f3 i explora si un quelant de ferro \u2014\u00e9s a dir, un tipus de f\u00e0rmac que neutralitza el ferro\u2014 podria prevenir la fibrosi hep\u00e0tica en reduir l’envelliment de les c\u00e8l\u00b7lules hep\u00e0tiques.<\/p>\n
Publicat a la revista Cell Death and Disease<\/em>, l’estudi utilitza un model experimental de dany hep\u00e0tic cr\u00f2nic en ratolins, indu\u00eft amb tetraclorur de carboni (CCl4), per examinar com l’acumulaci\u00f3 de ferro es relaciona amb la fibrosi hep\u00e0tica i l’envelliment cel\u00b7lular. Els investigadors han descobert que durant la progressi\u00f3 de la fibrosi hep\u00e0tica, el ferro s’acumula al fetge, cosa que coincideix amb l’aparici\u00f3 d’\u00e0rees fibroses i c\u00e8l\u00b7lules hep\u00e0tiques envellides. Els resultats sorgeixen d’un projecte Retos-Colaboraci\u00f3n finan\u00e7at per l’Ag\u00e8ncia Estatal de Recerca dut a terme per investigadors de l’IDIBELL (Josep Amengual i Isabel Fabregat), del CIC bioGUNE (M Luz Mart\u00ednez-Chantar) \u2014tots dos pertanyents al CIBEREHD\u2014, i de l\u2019IRB Barcelona (Manuel Serrano i Mate Maus, actual l\u00edder del Grup d’Envelliment i C\u00e0ncer de la Vall d’Hebron Institut d’Oncologia \u2013 VHIO).<\/p>\n Els hepat\u00f2cits, les c\u00e8l\u00b7lules principals del fetge, dels animals tractats van mostrar un perfil d’expressi\u00f3 de gens (conegut com a signatura transcript\u00f2mica) relacionat amb l’acumulaci\u00f3 de ferro i l’envelliment cel\u00b7lular. Aquesta signatura inclo\u00efa tamb\u00e9 l’activaci\u00f3 de gens relacionats amb l’estr\u00e8s oxidatiu, l’activaci\u00f3 la via del TGF-beta i la inhibici\u00f3 del metabolisme oxidatiu.<\/p>\n El tractament amb deferiprona, un quelant de ferro, va reduir l’acumulaci\u00f3 de ferro, la fibrosi i l’envelliment cel\u00b7lular al fetge dels ratolins. A m\u00e9s, el perfil de les prote\u00efnes secretades per les c\u00e8l\u00b7lules envellides va canviar cap a un perfil m\u00e9s antiinflamatori.<\/p>\n En experiments amb c\u00e8l\u00b7lules hep\u00e0tiques humanes, es va observar que el ferro s’acumulava en resposta a un agent que indueix envelliment cel\u00b7lular, i que la deferiprona podia prevenir aquest envelliment i els seus efectes associats. Tot i aix\u00f2, la deferiprona no va tenir un efecte significatiu en les c\u00e8l\u00b7lules estrellades hep\u00e0tiques, que tamb\u00e9 juguen un paper en la fibrosi hep\u00e0tica.<\/p>\n En conclusi\u00f3, l\u2019estudi demostra que l\u2019acumulaci\u00f3 de ferro \u00e9s un factor important en la progressi\u00f3 de la fibrosi hep\u00e0tica i l\u2019envelliment cel\u00b7lular. Les troballes suggereixen que l’\u00fas de quelants de ferro podria ser una estrat\u00e8gia efectiva per alentir o prevenir la fibrosi hep\u00e0tica en reduir l’envelliment cel\u00b7lular als hepat\u00f2cits. Aquest fet podria obrir noves oportunitats per al tractament de malalties hep\u00e0tiques cr\u00f2niques i millorar la qualitat de vida dels pacients afectats.<\/p>\n \u00a0<\/em><\/p>\n L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Investigadors de l’IDIBELL, el CIC bioGUNE, el CIBEREHD i l’IRB Barcelona demostren que l’acumulaci\u00f3 de ferro \u00e9s un factor important en la progressi\u00f3 de la fibrosi hep\u00e0tica i l’envelliment cel\u00b7lular. L\u2019estudi suggereix que l\u2019administraci\u00f3 de quelants de ferro podria ser una estrat\u00e8gia efectiva per alentir o prevenir la fibrosi hep\u00e0tica.<\/p>\n","protected":false},"author":8,"featured_media":26283,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,360],"tags":[],"class_list":["post-26282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-tgf-beta-i-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 11:36:45","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26282"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26282\/revisions"}],"predecessor-version":[{"id":26285,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26282\/revisions\/26285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26283"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}